CN103205423A - Prostate cancer biomarker miR-126-5P, diagnostic kit and application - Google Patents
Prostate cancer biomarker miR-126-5P, diagnostic kit and application Download PDFInfo
- Publication number
- CN103205423A CN103205423A CN2013101249888A CN201310124988A CN103205423A CN 103205423 A CN103205423 A CN 103205423A CN 2013101249888 A CN2013101249888 A CN 2013101249888A CN 201310124988 A CN201310124988 A CN 201310124988A CN 103205423 A CN103205423 A CN 103205423A
- Authority
- CN
- China
- Prior art keywords
- prostate cancer
- mir
- diagnostic kit
- application
- cancer biomarker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the field of biotechnology, and in particular relates to a prostate cancer biomarker miR-126-5P, a diagnostic kit and an application. The miR-126-5P is a miRNA (microribonucleic acid). The diagnostic kit is used for detecting the content of the miR-126-5P in the serum of a testee and comparing the content of the miR-126-5P with that of the miR-126-5P in a normal level so as to diagnose the prostate cancer. Therefore, the novel biomarker miR-126-5P is provided and is applied to the preparation of the diagnostic kit for diagnosing the prostate cancer. The biomarker miR-126-5P and the diagnostic kit containing the biomarker miR-126-5P, which are used for diagnosing the prostate cancer, are simple to operate, convenient in material obtainment, safe and free of causing wounds, and also have the characteristics of being high in specificity and sensitivity and easy in a great amount of screening. The biomarker miR-126-5P is especially suitable for reagents in the fields of the screening of people at high risks of the prostate cancer, the identification of the prostate cancer, the monitoring of the prostate cancer treating condition, the monitoring of the prostate cancer guiding medication, the prognosis monitoring of the prostate cancer and the like.
Description
Technical field
The present invention relates to biological technical field, be specifically related to a kind of prostate cancer biomarker miR-126-5P, diagnostic kit and application, relate in particular to prostate cancer molecular marker miR-126-5P in fields such as the monitoring of the monitoring of the evaluation of prostate cancer high risk population's screening, prostate cancer, prostate cancer therapy situation, prostate cancer direction of medication usage and prostate cancer prognosis monitorings with the application in the reagent.
Background technology
MicroRNA(miRNA) being a class is about the non-coding strand microRNA molecules of 22 Nucleotide by the length of native gene coding, and it has multiple important regulatory role in cell.Each miRNA can have a plurality of target genes, and several miRNA also can regulate same gene.This complicated adjusting network both can be regulated and control a plurality of expression of gene by a miRNA, also can come certain expression of gene of finely regulating by the combination of several miRNA.By inference, miRNA is regulating the gene of one of trichotomy.MicroRNA plays an increasingly important role at aspects such as disease incidence Mechanism Study, early diagnosis, individualized treatment and prognosis because its characteristics such as conservative property, space-time specificity, stability and tissue specificity highly make it be better than other biological marks such as protein, dna fragmentation.
Patients with prostate cancer mainly is elderly men, generally 50 years old with sequela, 95% betides the elderly men more than 60 years old, incidence increases with age growth constantly.In the U.S., the sickness rate of prostate cancer has surpassed lung cancer, becomes the tumour of first harm men's health.The sickness rate of Asia prostate cancers such as China is well below American-European countries, but presents ascendant trend in recent years.Even the early stage many no any symptoms of prostate cancer uncomfortable to some extent, also are not enough to cause patient's attention.When tumour increases the compressing urethra, often obscure mutually with hyperplasia of prostate again.Patient in China about 80% at first finds the distant metastasis focus, just finds prostate cancer then.At this moment, pathology has belonged to late period, prognosis mala.
At present, the clinical diagnosis mode of prostate cancer mainly contains following several: digital rectal examination, serum prostate specific antigen (PSA) detection, the detection of endorectal ultrasonography ripple, living tissue pathologic finding etc.Digital rectal examination is method the simplest, most economical practicality, mainly is the forefinger touch prostate gland by the doctor, in order to find a lot of asymptomatic patients with prostate cancer, might obtain the chance of early diagnosis and radical cure.But all there is certain limitation in aforesaid method.Limitation as digital rectal examination is: fail to pinpoint a disease in diagnosis when patient's prostate gland lump is little easily (1); (2) the patient's prostate cancer enlargement that has is not obvious, but has belonged to late period, is difficult for radical cure; (3) patient there is certain harm that do not accommodate, when patient's rectum has illness, can not uses this detection; (4) when the doctors experience deficiency, fail to pinpoint a disease in diagnosis or the mistaken diagnosis possibility.PSA under the normal circumstances in the blood not high (not being higher than 4ng/ml), PSA raises when being in prostate cancer and other prostatosis disease states, become the most responsive knurl mark of present examination prostate cancer, but also there is certain limitation in it: (1) need get blood examination and survey, and the patient is had certain damage; (2) PSA increases and also is common in non-prostate cancer disease, as prostatitis, prostatomegaly etc., therefore is difficult for making a definite diagnosis; (3) PSA increases when making a definite diagnosis prostate cancer, and often the patient has belonged to the intermediary and later stages, does not reach the purpose of early diagnosis.Prostate gland ultrasound examination directly perceived, not damaged easy and simple to handle, size, number, position, density, edge, form, the form that has or not calcification and calcification, size, number, substep and the halo on every side by showing lump, skin change etc. provide locatees and qualitative sign and judge the character of pathology: its limitation is: fail to pinpoint a disease in diagnosis easily to the little cancer kitchen range of compactness (1); (2) can not provide clear and definite etiologic diagnosis sometimes; (3) so can not show that because of it internal structure of tumour and surrounding tissue diagnostic accordance rate are very low; (4) some good pernicious lumps of real property that lack typical sign there is higher misdiagnosis rate.The living tissue pathologic finding is traumatic because of it, complicacy can not be as the means of primary dcreening operation, but its gold standard that to be prostate cancer make a definite diagnosis, general and additive method technical battery usefulness.
Studies show that in recent years, prostate cancer is closely related with miRNA, and they may participate in generation, development and the transfer of tumour, so to the detection of the pathogenesis of tumour, early diagnosis, individualized treatment, transfer and prognosis etc. corresponding effect may be arranged.The miRNA kind relevant with prostate cancer more and the effect differ, there are some researches show that the miRNA that raises comprises miR-375 in patients with prostate cancer, miR-148a, miR-200c, miR-106a, mir-128, miR-126-5P8, miR-20a and miR-30b etc.; The miRNA of downward modulation comprises miR-143, miR-145, miR-199a-5p, miR-223, miR-27a, miR-152 and miR-424 etc.Though carried out some researchs in this field, all there is deficiency the accuracy of existing miRNA mark, susceptibility aspect, in clinical and research, still there is the demand of seeking more accurate and sensitive prostate cancer miRNA mark.
In research process, find, the content of miR-126-5P in patients with prostate cancer serum is than the content height in the normal human serum, and after patients with prostate cancer was receiving operation, the content of the miR-126-5P in its serum just fell back to the normal level the same with content in the normal human serum.This shows that the patient exists close dependency at the miR-126-5P that increases during one's sickness and the tumour of prostate cancer.
Summary of the invention
In order to overcome above-mentioned the deficiencies in the prior art, the invention provides a kind of accuracy and susceptibility higher prostate cancer biomarker miR-126-5P, diagnostic kit and this biomarker in prostate cancer high risk population screening, diagnosis, treatment condition monitoring, prognosis Application in Monitoring.
In order to solve the problems of the technologies described above, the technical solution adopted in the present invention is:
A kind of prostate cancer biomarker miR-126-5P is characterized in that described miR-126-5P is a kind of miRNA, and the nucleotides sequence of miR-126-5P is classified as: SEQ ID NO.15 '-CATTATTACTTTTGGTAC-3 '.
The application of aforesaid prostate cancer biomarker miR-126-5P in the test kit of preparation prostate cancer high risk population screening, diagnosis, treatment condition monitoring, prognosis monitoring.
The application of aforesaid prostate cancer biomarker miR-126-5P in the test kit of preparation prostate cancer high risk population screening, diagnosis, treatment condition monitoring, prognosis monitoring, by the content of miR-126-5P in the detection subject serum, and compare to carry out the prostate cancer high risk population with normal level miR-126-5P content and screen, diagnose, treat condition monitoring, prognosis monitoring.
The application of aforesaid prostate cancer biomarker miR-126-5P in the test kit of preparation prostate cancer high risk population screening, diagnosis, treatment condition monitoring, prognosis monitoring, the content of miR-126-5P extracts, adds polyA tail, RT-PCR, quantitative PCR by total RNA and detects in described subject's serum.
Use the diagnostic kit of prostate cancer biomarker miR-126-5P, it is characterized in that, comprise: serum total RNA extraction reagent, RNA add polyA reagent, RT-PCR reagent, quantitative PCR reagent, and described quantitative PCR reagent comprises the specificity forward primer of miR-126-5P.
The diagnostic kit of aforesaid application prostate cancer biomarker miR-126-5P, the sequence of described specificity forward primer is: SEQ ID NO.75 '-UUGAGCAACGCGAACAAAUCA-3 '.
The diagnostic kit of aforesaid application prostate cancer biomarker miR-126-5P comprises in the serum total RNA extraction reagent in the described diagnostic kit that nucleotides sequence classifies the external source contrast-1 of SEQ ID NO.2 as, is 5 '-CAACCTCCTAGAAA GA-3 '.
The diagnostic kit of aforesaid application prostate cancer biomarker miR-126-5P, RNA adds and comprises in the polyA reagent that nucleotides sequence classifies the external source contrast-2 of SEQ ID NO.3 as in the described diagnostic kit, is 5 '-TGAGCAACGCGAACA A-3 '.
The diagnostic kit of aforesaid application prostate cancer biomarker miR-126-5P, comprise in the RT-PCR reagent in the described diagnostic kit that sequence is the RT-primer of SEQ ID NO.4, be 5 '-CAGTGGTATCAACGCACTCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTVN-3 ', wherein V is any among A, C and the G, and N is any among A, T, C and the G.
The diagnostic kit of aforesaid application prostate cancer biomarker miR-126-5P, comprise in the quantitative PCR reagent in the described diagnostic kit that nucleotides sequence classifies SEQ ID NO.5(5 '-CTCACAC GACTCACGACAC-3 ' as) general reverse primer UPM-short-movie section and nucleotides sequence classify SEQ ID NO.6(5 '-CTCACACGACTCACGACACC AGTGGTATCAACGCACTC-3 ' as) general reverse primer UPM-long segment.
The present invention provides a kind of new molecular marker miR-126-5P for the diagnosis of prostate cancer, and be applied to prepare this molecular marker in the diagnostic kit of diagnosing prostate cancer, use this molecular marker and contain the diagnostic kit diagnosing prostate cancer of this molecular marker, simple to operate, draw materials conveniently, the no wound of safety, and has high specific, high sensitivity and the characteristics that are easy to a large amount of examinations, this molecular marker is particularly suitable for being applied to prostate cancer high risk population's screening, the evaluation of prostate cancer, the monitoring of prostate cancer therapy situation, fields such as the monitoring of prostate cancer direction of medication usage and prostate cancer prognosis monitoring are with in the reagent.
Embodiment
For making the present invention easier to understand, further set forth the present invention below in conjunction with specific embodiment, but following embodiment only is not used in for explanation the present invention and limits the scope of the invention, and NM concrete experimental technique in the following example carries out according to the normal experiment method usually.
1. the extraction of total RNA in serum or the blood plasma:
Extract preceding 7 days of 3 prostate gland corrective surgeries and perform the operation back 7 days blood each 2 milliliters, extract simultaneously the same period 3 normal human bloods each 2 milliliters in contrast.Centrifugal with carrying out behind the above-mentioned blood coagulation, get 1 milliliter of upper serum at last and place 1.5 milliliters no DNA and the centrifuge tube of RNA pollution.
Use Beijing health to extract test kit as the century RNA that produces of bio tech ltd and extracts total RNA in above-mentioned serum, adding 1 microlitre external source contrast-1(Beijing Quanto Biotechnology Co., Ltd. provides in per 250 microlitre serum) monitor the extraction quality of RNA in the above-mentioned serum.The total RNA that extracts is by using Therm NanoDrop2000c spectrophotometer, the concentration determination that the ratio of mensuration 260/280nm ultraviolet wavelength carries out.The sequence of described external source contrast-1 is 5 '-CAACCTCCTAGAAAGA-3 ' (SEQ ID NO:2).
2. the microRNA in the detection by quantitative serum:
1) add poly(A) tail:
Preparation adds the reaction solution of A tail in the PCR of no RNA enzyme pipe (VWR company produces, 200 microlitres), and the system total amount is 20 microlitres.Adding the special external source contrast-2(Beijing Quanto Biotechnology Co., Ltd. of 1 microlitre in per 20 microlitre system reaction solutions provides) monitor tailing and the reverse transcription quality of miRNA, described reaction solution system is as shown in table 1.Put into PCR instrument (Thermo) with the PCR pipe for preparing reaction solution is housed, under 37 ℃, hatched 1 hour, obtain incubation reaction liquid I.
The sequence of described external source contrast-2 is 5 '-TGAGCAACGCGAACAA-3 ' (SEQ ID NO:3).
Table 1 adds polyA reagent and forms
| Component | Add-on (microlitre) |
| The external source contrast-2(20nm) | 1 |
| E.Coli polyA polymerase (takara company) | 0.5 |
| E.Coli polyA10 times of polymerase damping fluid | 2 |
| Deoxidation gland sweet (10mm) | 2 |
| RNA | x |
| The ultrapure water that no RNA and DNA pollute | 14-x |
| The RNA enzyme inhibitors | 0.5 |
| Total amount | 20 |
X represents that the RNA volume that adds determined by the concentration of RNA in the table, is x=500 nanogram/RNA concentration in this experiment.
2) RT-PCR obtains the cDNA strand:
To through 1) add the RT-primer (the spacious rich living technology in Beijing company limited provides) of 0.5 microlitre (0.5 nanogram/microlitre) in the reaction solution I that obtains after hatching, hatched under 70 ℃ 5 minutes, and hatched and to hatch gained reaction solution II after the end and put into ice bath immediately at least 2 minutes; Then according to becoming assignment system inverse transcription reaction liquid III shown in the table 2; Gained inverse transcription reaction liquid III after hatching 50 minutes under 50 ℃, is incubated 15 minutes down at 70 ℃, is positioned over after insulation finishes and cools off in the ice bath, obtain cDNA.Carry out packing after the cDNA that obtains can being diluted to the reverse transcription product that contains the total RNA of 1 nanogram in the 1 microlitre system, be positioned over subzero 20 degree and preserve.The sequence of described RT-primer is 5 '-CAGTGGTATCAACGCACTCCTTTTTTTTT TTTTTTTTTTTTTTTTTTTTTVN-3 ' (SEQ ID NO:4), and wherein V is any among A, C and the G, and N is any among A, T, C and the G.
Table 2RT-PCR reagent is formed
3) QPCR detection by quantitative:
In 2 milliliters of EP pipes (production of VWR company), prepare the reaction solution IV as table 3 dosage; After the reaction solution IV for preparing fully put upside down mixing, divide in the 96 holes point end PCR plate of packing into (production of VWR company) every Kong Zhongwei 18 microlitres; Use the volley of rifle fire (Gibson company, the 1-10 microlitre) adding the specificity forward primer in the above-mentioned hole (is GSP external source contrast-3, GSP refers to gene-specific primer, provided by Beijing Quanto Biotechnology Co., Ltd.), the sequence of this Auele Specific Primer is 5 '-UUGAGCAACGCGAACAAAUCA-3 ' (SEQ ID NO:7), and every hole is 2 microlitres; Add respectively in the above-mentioned hole then behind the 10 microlitre paraffin oils with putting into ABI 7900PCR detection by quantitative instrument after special-purpose pad pasting (VWR company) sealing, the setting degree is as shown in table 4.
Table 3 quantitative PCR reagent is formed
The short-movie section of 10 * UPM-described in the table 3 and 10 * UPM-long segment are general reverse primer, and wherein the nucleotides sequence of the general reverse primer of 10 * UPM-short-movie section is classified 5 '-CTCACACGACTCACGACAC-3 ' (SEQ ID NO:5) as; The nucleotides sequence of described 10 * UPM-long segment is classified 5 '-CTCACACGACTC ACGACACCAGTGGTATCAACGCACTC-3 ' (SEQ ID NO:6) as.
Table 4 quantitative PCR reaction conditions
3. adopt Array Tools4.1.0 to carry out data analysis: can record target miRNA in the sample serum and be that external source contrasts-1 with reference to miRNA(with aforesaid method) the Ct value, try to achieve the relative content of target miRNA in serum according to the Ct value level of reference.Before can recording the prostate cancer art, prostate cancer postoperative 7 days and each sample peripheral blood of normal control clear in the average delta Ct value of miR-126-5P be respectively 0.44,5.20 and 0.95, the result shows that the relative content of miR-126-5P in the prostate cancer peripheral blood obviously reduces than normal control group, and the content of 7 days miR-126-5P of postoperative is apparently higher than the normal value level.Single factor Cox risk regression analysis and K-M survival analysis show that miR-126-5P can be used as the biomarker that development takes place prostate cancer.
The standardization of data: the Ct value with external source contrast-1 is reference, tries to achieve the relative content of miRNA in the serum, and the result shows that miR-126-5P relative content in the serum before patient's art significantly reduces, and postoperative significantly increased in seven days.With 2 of classics in the qPCR detection
-Δ CtMode represent the level (Δ Ct is Ct value poor of target miRNA and external source contrast-1) of purpose miRNA in the serum.
4. according to the horizontal diagnosing prostate cancer of purpose miRNA in the serum:
Compare with the low levels of miR-126-5P in the normal control serum, the downward modulation of the expression level of miR-126-5P is more than 2 times in the serum before the patients with prostate cancer art, and difference has statistical significance; The miR-126-5P expression level is compared with normal control and is increased by 500 abovely in statistical results show patient's postoperative serum, and difference has statistical significance.
More than show and described ultimate principle of the present invention, principal character and advantage of the present invention.The technician of the industry should understand; the present invention is not restricted to the described embodiments; that describes in above-described embodiment and the specification sheets just illustrates principle of the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications, and these changes and improvements all fall in the claimed scope of the invention.The claimed scope of the present invention is defined by appending claims and equivalent thereof.
Claims (10)
1. a prostate cancer biomarker miR-126-5P is characterized in that, described miR-126-5P is a kind of miRNA, and the nucleotides sequence of miR-126-5P is classified as: SEQ ID NO.1 5 '-CATTATTACTTTTGGTAC-3 '.
2. the application of the described prostate cancer biomarker of claim 1 miR-126-5P in the test kit of preparation prostate cancer high risk population screening, diagnosis, treatment condition monitoring, prognosis monitoring.
3. the application of prostate cancer biomarker miR-126-5P according to claim 2 in the test kit of preparation prostate cancer high risk population screening, diagnosis, treatment condition monitoring, prognosis monitoring, it is characterized in that: by the content of miR-126-5P in the detection subject serum, and compare to carry out the prostate cancer high risk population with normal level miR-126-5P content and screen, diagnose, treat condition monitoring, prognosis monitoring.
4. the application of prostate cancer biomarker miR-126-5P according to claim 3 in the test kit of preparation prostate cancer high risk population screening, diagnosis, treatment condition monitoring, prognosis monitoring is characterized in that: the content of miR-126-5P extracts, adds polyA tail, RT-PCR, quantitative PCR by total RNA and detects in described subject's serum.
5. use the diagnostic kit of prostate cancer biomarker miR-126-5P, it is characterized in that, comprise: serum total RNA extraction reagent, RNA add polyA reagent, RT-PCR reagent, quantitative PCR reagent, and described quantitative PCR reagent comprises the specificity forward primer of miR-126-5P.
6. the diagnostic kit of application prostate cancer biomarker miR-126-5P according to claim 5 is characterized in that the sequence of described specificity forward primer is: SEQ ID NO.7 5 '-UUGAGCAACGCGAACAAAUCA-3 '.
7. according to the diagnostic kit of claim 5 or 6 described application prostate cancer biomarker miR-126-5P, it is characterized in that: comprise in the serum total RNA extraction reagent in the described diagnostic kit that nucleotides sequence classifies the external source contrast-1 of SEQ ID NO.2 as.
8. the diagnostic kit of application prostate cancer biomarker miR-126-5P according to claim 7 is characterized in that: RNA adds and comprises in the polyA reagent that nucleotides sequence classifies the external source contrast-2 of SEQ ID NO.3 as in the described diagnostic kit.
9. the diagnostic kit of application prostate cancer biomarker miR-126-5P according to claim 7, it is characterized in that: comprise in the RT-PCR reagent in the described diagnostic kit that sequence is the RT-primer of SEQ ID NO.4, wherein V is any among A, C and the G, and N is any among A, T, C and the G.
10. the diagnostic kit of application prostate cancer biomarker miR-126-5P according to claim 7, it is characterized in that: comprise in the quantitative PCR reagent in the described diagnostic kit that nucleotides sequence classifies the general reverse primer UPM-short-movie section of SEQ ID NO.5 and the general reverse primer UPM-long segment that nucleotides sequence is classified SEQ ID NO.6 as.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101249888A CN103205423A (en) | 2013-04-11 | 2013-04-11 | Prostate cancer biomarker miR-126-5P, diagnostic kit and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101249888A CN103205423A (en) | 2013-04-11 | 2013-04-11 | Prostate cancer biomarker miR-126-5P, diagnostic kit and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103205423A true CN103205423A (en) | 2013-07-17 |
Family
ID=48752829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101249888A Pending CN103205423A (en) | 2013-04-11 | 2013-04-11 | Prostate cancer biomarker miR-126-5P, diagnostic kit and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103205423A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104531856A (en) * | 2014-12-19 | 2015-04-22 | 王振宁 | Gastric cancer process and prognosis related molecular marker miR-1258 |
| CN106148555A (en) * | 2016-09-09 | 2016-11-23 | 北京致成生物医学科技有限公司 | LOC100130238 is as molecular marked compound and the application thereof detecting carcinoma of prostate |
| CN108728535A (en) * | 2018-05-26 | 2018-11-02 | 复旦大学 | Applications of the hsa_circ_0049154 as prostate cancer molecular target in preparing drug and kit |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102839172A (en) * | 2012-08-24 | 2012-12-26 | 中国医科大学附属第一医院 | HIV (Human immunodeficiency virus) infection disease progression molecule marker miR-503 |
-
2013
- 2013-04-11 CN CN2013101249888A patent/CN103205423A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102839172A (en) * | 2012-08-24 | 2012-12-26 | 中国医科大学附属第一医院 | HIV (Human immunodeficiency virus) infection disease progression molecule marker miR-503 |
Non-Patent Citations (2)
| Title |
|---|
| ALLA MUSIYENKO ,ET AL: "Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells", 《J MOL MED (BERL)》 * |
| NATASCHA BUSHATI: "Determination of a general mode of microRNA action and functional characterization of specific microRNAs in Drosophila melanogaster", 《UNIVERSITY OF VIENNA》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104531856A (en) * | 2014-12-19 | 2015-04-22 | 王振宁 | Gastric cancer process and prognosis related molecular marker miR-1258 |
| CN106148555A (en) * | 2016-09-09 | 2016-11-23 | 北京致成生物医学科技有限公司 | LOC100130238 is as molecular marked compound and the application thereof detecting carcinoma of prostate |
| CN108728535A (en) * | 2018-05-26 | 2018-11-02 | 复旦大学 | Applications of the hsa_circ_0049154 as prostate cancer molecular target in preparing drug and kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106978480A (en) | Molecular diagnostic assay for cancer | |
| Shah et al. | Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer | |
| CN106701986A (en) | Application of molecular marker in diagnosis and treatment of gastric carcinoma | |
| CN105316340A (en) | MIR27A-3P serving as prostate cancer molecular marker and application of same to diagnostic reagent kit | |
| CN111218509A (en) | Novel diagnostic marker PPEF1 for breast cancer and application thereof | |
| CN105154448A (en) | Prostatic cancer molecular target RP11-1023L17.1 and application thereof to diagnostic kit | |
| US20140309130A1 (en) | Use of MicroRNAs for Screening and Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia | |
| US20190185945A1 (en) | Biomarkers of Oral, Pharyngeal and Laryngeal Cancers | |
| CN104694623A (en) | Plasma miRNA marker for diagnosis of lung cancer and application | |
| CN103074431B (en) | Special primer, kit and method for testing minRNA-128 in colorectal cancer serum | |
| CN103205423A (en) | Prostate cancer biomarker miR-126-5P, diagnostic kit and application | |
| TWI571514B (en) | Method for accessing the risk of having colorectal cancer | |
| CN101665834A (en) | Ki67mRNA real-time fluorescence quantitative RT-PCR detection reagent kit | |
| CN110257514A (en) | A kind of new cancer of the esophagus blood miRNA marker and its application | |
| CN110396542A (en) | A kind of LncRNA marker and its application in diabetes | |
| CN111808966B (en) | Application of miRNA in diagnosis of breast cancer disease risk | |
| CN108753981A (en) | Application of the quantitative detection of HOXB8 genes in colorectal cancer Index for diagnosis | |
| CN103361415A (en) | Prostate cancer biomarker miR-379 and diagnostic kit as well as application of prostate cancer biomarker miR-379 | |
| CN103627704A (en) | Prostatic cancer molecular marker miR-19a and applications thereof | |
| CN103667282A (en) | Molecular marker miR-628-3P for prostatic cancer and application of molecular marker miR-628-3P | |
| CN106191275A (en) | The application in diagnosis three female breast carcinoma of a kind of compositions | |
| CN103215359A (en) | Prostatic cancer biomarker miR-21*, diagnostic kit and application of prostatic cancer biomarker miR-21* | |
| CN102899390A (en) | Small cell lung cancer markers and their detection | |
| CN114746551A (en) | Marker for diagnosing colorectal cancer, method for assisting diagnosis of colorectal cancer, method for collecting data to be used for diagnosis of colorectal cancer, diagnostic kit for colorectal cancer, therapeutic agent for colorectal cancer, method for treating colorectal cancer, and method for diagnosing colorectal cancer | |
| Davarinejad et al. | Identifying miRNA signature for predicting and treatment of breast cancer using the transcriptomic data of 7,000 breast tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130717 |